Dewpoint secures $60M for condensates-drugging platform


Dewpoint Therapeutics Inc., a U.S.-German startup working to industrialize the drugging of biomolecular condensates – membraneless compartments found inside cells – has launched with a $60 million series A led by its founding investor, Polaris Partners. Full story.